Tango Therapeutics, Inc. TNGX
We take great care to ensure that the data presented and summarized in this overview for Tango Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TNGX
View all-
Trv Gp Iv, LLC Boston, MA16.9MShares$68.8 Million80.09% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$54.4 Million4.45% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$33.5 Million3.35% of portfolio
-
Nextech Invest Ag5.53MShares$22.6 Million6.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.02MShares$20.5 Million0.02% of portfolio
-
Southpoint Capital Advisors LP New York, NY5MShares$20.4 Million1.08% of portfolio
-
Black Rock Inc. New York, NY3.99MShares$16.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.65MShares$14.9 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.71MShares$11.1 Million3.75% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.69MShares$11 Million0.0% of portfolio
Latest Institutional Activity in TNGX
Top Purchases
Top Sells
About TNGX
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Insider Transactions at TNGX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 18
2024
|
Mace Rothenberg |
BUY
Open market or private purchase
|
Direct |
10,000
+24.24%
|
$30,000
$3.78 P/Share
|
|
Nov 14
2024
|
Mace Rothenberg |
BUY
Open market or private purchase
|
Direct |
10,000
+32.0%
|
$30,000
$3.62 P/Share
|
|
Nov 07
2024
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,205,442
-5.12%
|
$3,616,326
$3.11 P/Share
|
|
Nov 06
2024
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
1,494,558
-11.21%
|
$4,483,674
$3.28 P/Share
|
|
Nov 06
2024
|
Boxer Capital Management, LLC |
SELL
Open market or private sale
|
Indirect |
3,080,000
-46.03%
|
$9,240,000
$3.14 P/Share
|
|
Oct 25
2024
|
Boxer Capital Management, LLC |
SELL
Open market or private sale
|
Direct |
633,000
-8.64%
|
$3,798,000
$6.87 P/Share
|
|
Oct 22
2024
|
Boxer Capital Management, LLC |
SELL
Open market or private sale
|
Direct |
250,000
-3.3%
|
$1,500,000
$6.78 P/Share
|
|
Oct 21
2024
|
Boxer Capital Management, LLC |
SELL
Open market or private sale
|
Direct |
625,000
-7.62%
|
$4,375,000
$7.05 P/Share
|
|
Sep 13
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
67,400
-0.4%
|
$674,000
$10.53 P/Share
|
|
Sep 05
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
75,000
-0.44%
|
$825,000
$11.56 P/Share
|
|
Aug 30
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
175,000
-1.02%
|
$1,925,000
$11.6 P/Share
|
|
Aug 27
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
25,000
-0.15%
|
$275,000
$11.55 P/Share
|
|
Aug 19
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
150,000
-0.86%
|
$1,500,000
$10.09 P/Share
|
|
Aug 16
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
135,000
-0.77%
|
$1,215,000
$9.79 P/Share
|
|
Aug 01
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
40,000
-0.23%
|
$360,000
$9.8 P/Share
|
|
Jul 31
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
100,000
-0.57%
|
$900,000
$9.93 P/Share
|
|
Jul 30
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
95,000
-0.54%
|
$855,000
$9.8 P/Share
|
|
Jul 26
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
50,000
-0.28%
|
$450,000
$9.84 P/Share
|
|
Jul 25
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
100,599
-0.56%
|
$905,391
$9.87 P/Share
|
|
Jul 24
2024
|
Third Rock Ventures Iv, L.P. |
SELL
Open market or private sale
|
Direct |
200,000
-1.11%
|
$1,800,000
$9.82 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 226K shares |
|---|---|
| Open market or private sale | 5K shares |
| Open market or private purchase | 20K shares |
| Open market or private sale | 10.4M shares |
|---|